A 239% single-day rally in CNSP has detonated the lending market. CNS Pharmaceuticals' cost to borrow hit 326% on May 4 — up from 22.8% just one week earlier.
That 1,170% weekly jump in borrow cost is the dominant signal here. For context, the stock traded at cost-to-borrow levels between 12% and 26% for the entire prior six weeks. The move to 326% is not a gradual tightening — it is a step-change driven by short sellers scrambling to fund or cover positions into a violent price spike.
SI stood at 12.6% of free float as of May 4 — up 59% in a single day. That is a meaningful position for a small pharma name. But the direction of travel matters: earlier in the week, SI had actually fallen to around 7.9% of float, suggesting some shorts had covered ahead of the move. Those who stayed in are now paying 326% annually to hold their borrow.
The availability of shares to borrow has tightened sharply alongside the cost spike. The lending market has gone from uncomfortable to punishing in 24 hours.
CNSP's ORTEX short score stood at 66.6 as of May 1 — placing it in the 13th percentile by short score rank. The utilization rank sits at the 3rd percentile: almost every share in the lending pool has been lent out. The 52-week peak utilization was 100%. The stock has spent most of April and May with utilization running above 90%.
That backdrop made CNSP structurally vulnerable to exactly this kind of price dislocation. A high-utilization, heavily-borrowed small-cap with limited shares available is the classic setup for a borrow squeeze when a catalyst hits.
The borrow market is repricing aggressively. Whether short sellers hold, cover, or are forced out by the cost of carry will define the next move in CNSP's lending dynamics.
See the live data behind this article on ORTEX.
Open CNSP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
